Avi Stern - Allovir CFO

ALVR
 Stock
  

USD 7.34  0.11  1.48%   

  CFO
Mr. Avi Stern is Chief Financial Officer of Alvarion Ltd. since March 2013. Mr. Stern joined Alvarion in 2009 as Director of Finance and as of 2011 served as Vice President of Finance. Prior to joining Alvarion Mr. Stern was Director of Finance at Finisar Corporationrationration from 2007 to 2009. Preceding this position from 2003 to 2007 Mr. Stern worked as a controller for Veraz Networks a provider of softswitch media gateway and digital compression solutions. From 2000 to 2003 Mr. Stern worked for ECI Telecom a networking infrastructure provider as Deputy Controller
Age: 39  CFO Since 2013      
617 433 2605  https://www.allovir.com
Stern is a Certified Public Accountant in Israel and holds both Bachelors and Masters degrees in Business Administration from The College of Management in Rishon LeZion, Israel.

Allovir Management Efficiency

Allovir has return on total asset (ROA) of (44.81) % which means that it has lost $44.81 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (83.35) %, meaning that it created substantial loss on money invested by shareholders. Allovir management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 22.51 M in liabilities with Debt to Equity (D/E) ratio of 0.14, which may suggest the company is not taking enough advantage from borrowing. Allovir has a current ratio of 8.02, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Allovir until it has trouble settling it off, either with new capital or with free cash flow. So, Allovir's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Allovir sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Allovir to invest in growth at high rates of return. When we think about Allovir's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 1 records

CFO Since

Robert LandryRegeneron Pharmaceuticals
2019
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell therapies to prevent and treat devastating viral-associated diseases. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. Allovir operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 107 people. Allovir (ALVR) is traded on NASDAQ Exchange in USA and employs 107 people.

Allovir Leadership Team

Elected by the shareholders, the Allovir's board of directors comprises two types of representatives: Allovir inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allovir. The board's role is to monitor Allovir's management team and ensure that shareholders' interests are well served. Allovir's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allovir's outside directors are responsible for providing unbiased perspectives on the board's policies.
Doron Inbar, Non-Executive Independent Director
Raphael Amit, External Director
Zeev Farkash, Executive Vice President - Sales
Assaf Katan, Acting President and CEO
Moshe Fourier, Executive Vice President-R&D
Tali Aben, Non-Executive Independent Director
Mati Wax, CTO
Avi Stern, CFO
Amnon Yacoby, Independent Chairman of the Board
Nir Golan, Executive Vice President
Ziv Eizenberg, Executive Vice President-Human Resources
Leor Porat, Executive Vice President General Counsel

Allovir Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allovir a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Allovir in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Allovir's short interest history, or implied volatility extrapolated from Allovir options trading.

Pair Trading with Allovir

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allovir position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Allovir could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allovir when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allovir - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allovir to buy it.
The correlation of Allovir is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allovir moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allovir moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allovir can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Trending Equities. You can also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for analysis

When running Allovir price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Is Allovir's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allovir. If investors know Allovir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allovir listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
683.8 M
Return On Assets
(0.38) 
Return On Equity
(0.72) 
The market value of Allovir is measured differently than its book value, which is the value of Allovir that is recorded on the company's balance sheet. Investors also form their own opinion of Allovir's value that differs from its market value or its book value, called intrinsic value, which is Allovir's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allovir's market value can be influenced by many factors that don't directly affect Allovir's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allovir's value and its price as these two are different measures arrived at by different means. Investors typically determine Allovir value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allovir's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.